256 related articles for article (PubMed ID: 1393035)
41. Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study.
Chesnut CH; Majumdar S; Newitt DC; Shields A; Van Pelt J; Laschansky E; Azria M; Kriegman A; Olson M; Eriksen EF; Mindeholm L
J Bone Miner Res; 2005 Sep; 20(9):1548-61. PubMed ID: 16059627
[TBL] [Abstract][Full Text] [Related]
42. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.
Reginster JY; Seeman E; De Vernejoul MC; Adami S; Compston J; Phenekos C; Devogelaer JP; Curiel MD; Sawicki A; Goemaere S; Sorensen OH; Felsenberg D; Meunier PJ
J Clin Endocrinol Metab; 2005 May; 90(5):2816-22. PubMed ID: 15728210
[TBL] [Abstract][Full Text] [Related]
43. Calcitonin for the long-term prevention and treatment of postmenopausal osteoporosis.
Body JJ
Bone; 2002 May; 30(5 Suppl):75S-79S. PubMed ID: 12008163
[TBL] [Abstract][Full Text] [Related]
44. [Clinical efficacy of treatment with salmon calcitonin, administered intranasally for 1 year, in stabilized postmenopausal osteoporosis].
Agnusdei D; Gonnelli S; Camporeale A; Batignani T; Nardi P; Ianes A; Gennari C
Minerva Endocrinol; 1989; 14(3):169-76. PubMed ID: 2695815
[TBL] [Abstract][Full Text] [Related]
45. Calcitonin.
Silverman SL
Rheum Dis Clin North Am; 2001 Feb; 27(1):187-96. PubMed ID: 11285994
[TBL] [Abstract][Full Text] [Related]
46. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
Black DM; Delmas PD; Eastell R; Reid IR; Boonen S; Cauley JA; Cosman F; Lakatos P; Leung PC; Man Z; Mautalen C; Mesenbrink P; Hu H; Caminis J; Tong K; Rosario-Jansen T; Krasnow J; Hue TF; Sellmeyer D; Eriksen EF; Cummings SR;
N Engl J Med; 2007 May; 356(18):1809-22. PubMed ID: 17476007
[TBL] [Abstract][Full Text] [Related]
47. Intranasal salmon calcitonin in postmenopausal osteoporosis: effect of different therapeutic regimens on vertebral and peripheral bone density.
Perrone G; Galoppi P; Valente M; Capri O; D'Ubaldo C; Anelli G; Zichella L
Gynecol Obstet Invest; 1992; 33(3):168-71. PubMed ID: 1612530
[TBL] [Abstract][Full Text] [Related]
48. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
[TBL] [Abstract][Full Text] [Related]
49. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D
J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
[TBL] [Abstract][Full Text] [Related]
50. A new biochemical marker of bone resorption for follow-up on treatment with nasal salmon calcitonin.
Overgaard K; Christiansen C
Calcif Tissue Int; 1996 Jul; 59(1):12-6. PubMed ID: 8661977
[TBL] [Abstract][Full Text] [Related]
51. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.
Ensrud KE; Black DM; Palermo L; Bauer DC; Barrett-Connor E; Quandt SA; Thompson DE; Karpf DB
Arch Intern Med; 1997 Dec 8-22; 157(22):2617-24. PubMed ID: 9531231
[TBL] [Abstract][Full Text] [Related]
52. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women.
Downs RW; Bell NH; Ettinger MP; Walsh BW; Favus MJ; Mako B; Wang L; Smith ME; Gormley GJ; Melton ME
J Clin Endocrinol Metab; 2000 May; 85(5):1783-8. PubMed ID: 10843152
[TBL] [Abstract][Full Text] [Related]
53. Increase of axial and appendicular trabecular and cortical bone density in established osteoporosis with intermittent nasal salmon calcitonin therapy.
Peichl P; Rintelen B; Kumpan W; Bröll H
Gynecol Endocrinol; 1999 Feb; 13(1):7-14. PubMed ID: 10368793
[TBL] [Abstract][Full Text] [Related]
54. Calcitonin intranasal--unigene: Salcatonin intranasal--unigene.
Drugs R D; 2004; 5(2):90-3. PubMed ID: 15293868
[TBL] [Abstract][Full Text] [Related]
55. Early effect of nasal salmon calcitonin on the bone marker Crosslaps.
Ofluoglu D; Karadag-Saygi E; Canbulat C; Gunduz OH; Kul-Panza E; Akyuz G
Rheumatol Int; 2006 Feb; 26(4):288-91. PubMed ID: 15875189
[TBL] [Abstract][Full Text] [Related]
56. A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture.
Palacios S; Silverman SL; de Villiers TJ; Levine AB; Goemaere S; Brown JP; De Cicco Nardone F; Williams R; Hines TL; Mirkin S; Chines AA;
Menopause; 2015 Aug; 22(8):806-13. PubMed ID: 25668306
[TBL] [Abstract][Full Text] [Related]
57. Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers.
Bone HG; Downs RW; Tucci JR; Harris ST; Weinstein RS; Licata AA; McClung MR; Kimmel DB; Gertz BJ; Hale E; Polvino WJ
J Clin Endocrinol Metab; 1997 Jan; 82(1):265-74. PubMed ID: 8989272
[TBL] [Abstract][Full Text] [Related]
58. Salmon calcitonin in the prevention of bone loss at perimenopause.
Arnala I; Saastamoinen J; Alhava EM
Bone; 1996 Jun; 18(6):629-32. PubMed ID: 8806006
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and tolerability of calcitonin in the prevention and treatment of osteoporosis.
Halkin V; Reginster JY
BioDrugs; 1998 Oct; 10(4):295-300. PubMed ID: 18020602
[TBL] [Abstract][Full Text] [Related]
60. The antifracture efficacy of alendronate.
Seeman E
Int J Clin Pract Suppl; 1999 Apr; 101():40-5. PubMed ID: 12675021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]